Table 4.

Prognostic factors for development of suspected non-alcoholic fatty liver disease in women with normal baseline transaminase concentrations in Italian tamoxifen chemoprevention trial. Values are hazard ratios (95% confidence intervals) obtained from Cox regression model

		Body mass index (kg/m2)		Treatment arm
Multivariate analysis	All women	<25	≥25	Placebo	Tamoxifen
Tamoxifen	2.0 (1.1 to 3.5)	1.2 (0.4 to 3.7)	2.3 (1.2 to 4.6)	-	-
Age	1.0 (0.9 to 1.0)	1.0 (0.9 to 1.0)	1.0 (0.9 to 1.0)	1.0 (0.9 to 1.0)	1.0 (0.9 to 1.0)
Body mass index 25-30	2.4 (1.2 to 4.8)	-	-	1.4 (0.4 to 4.2)	3.2 (1.3 to 7.9)
Body mass index >30	3.6 (1.7 to 7.6)	-	-	2.0 (0.6 to 7.0)	5.4 (2.1 to 14.1)
Diabetes	1.9 (0.6 to 6.2)	-	2.3 (0.7 to 7.6)	10.6 (2.9 to 38.6)	-
Cholesterol 6.5-7.8 mmol/l	1.3 (0.7 to 2.5)	1.4 (0.3 to 5.6)	1.3 (0.6 to 2.7)	2.4 (0.8 to 7.0)	0.9 (0.4 to 2.1)
Cholesterol >7.8 mmol/l	3.4 (1.4 to 7.8)	7.7 (1.9 to 31.8)	2.3 (0.8 to 6.8)	8.4 (2.5 to 28.3)	2.2 (0.6 to 7.4)
Hypertension*	2.0 (1.0 to 3.8)	2.0 (0.4 to 9.2)	2.1 (1.0 to 4.3)	2.0 (0.7 to 6.1)	2.0 (0.9 to 4.5)

^*Normalised by treatment.